Terms: = Brain cancer AND KIF5B, ENSG00000170759, 3799, P33176, UKHC, KNS1, KNS, KINH
16 results:
1. Combined large cell neuroendocrine carcinoma, lung adenocarcinoma, and squamous cell carcinoma: a case report and review of the literature.
Zhu Z; Liu Y; Xu H; Ning H; Xia Y; Shen L
J Cardiothorac Surg; 2023 Aug; 18(1):254. PubMed ID: 37653509
[TBL] [Abstract] [Full Text] [Related]
2. Intracranial Activity of Selpercatinib in Chinese Patients With Advanced
Cheng Y; Huang D; Zhou J; Zhou C; Sun Y; Wu L; Guo Y; Jingxin S; Zhang W; Lu S
JCO Precis Oncol; 2023 Jun; 7():e2200708. PubMed ID: 37315261
[TBL] [Abstract] [Full Text] [Related]
3. Central Nervous System Disease in Patients With RET Fusion-Positive NSCLC Treated With Selpercatinib.
Murciano-Goroff YR; Falcon CJ; Lin ST; Chacko C; Grimaldi G; Liu D; Wilhelm C; Iasonos A; Drilon A
J Thorac Oncol; 2023 May; 18(5):620-627. PubMed ID: 36657661
[TBL] [Abstract] [Full Text] [Related]
4. Pralsetinib in RET fusion-positive non-small-cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP).
Passaro A; Russo GL; Passiglia F; D'Arcangelo M; Sbrana A; Russano M; Bonanno L; Giusti R; Metro G; Bertolini F; Grisanti S; Carta A; Cecere F; Montrone M; Massa G; Perrone F; Simionato F; Guaitoli G; Scotti V; Genova C; Lugini A; Bonomi L; Attili I; de Marinis F
Lung Cancer; 2022 Dec; 174():118-124. PubMed ID: 36379124
[TBL] [Abstract] [Full Text] [Related]
5. Base-resolution methylomes of gliomas bearing histone H3.3 mutations reveal a G34 mutant-specific signature shared with bone tumors.
Sangatsuda Y; Miura F; Araki H; Mizoguchi M; Hata N; Kuga D; Hatae R; Akagi Y; Amemiya T; Fujioka Y; Arai Y; Yoshida A; Shibata T; Yoshimoto K; Iihara K; Ito T
Sci Rep; 2020 Sep; 10(1):16162. PubMed ID: 32999376
[TBL] [Abstract] [Full Text] [Related]
6. ALK-positive Histiocytosis of the Breast: A Clinicopathologic Study Highlighting Spindle Cell Histology.
Kashima J; Yoshida M; Jimbo K; Izutsu K; Ushiku T; Yonemori K; Yoshida A
Am J Surg Pathol; 2021 Mar; 45(3):347-355. PubMed ID: 32826530
[TBL] [Abstract] [Full Text] [Related]
7. ALK-positive histiocytosis: an expanded clinicopathologic spectrum and frequent presence of kif5b-ALK fusion.
Chang KTE; Tay AZE; Kuick CH; Chen H; Algar E; Taubenheim N; Campbell J; Mechinaud F; Campbell M; Super L; Chantranuwat C; Yuen ST; Chan JKC; Chow CW
Mod Pathol; 2019 May; 32(5):598-608. PubMed ID: 30573850
[TBL] [Abstract] [Full Text] [Related]
8. Selective RET kinase inhibition for patients with RET-altered cancers.
Subbiah V; Velcheti V; Tuch BB; Ebata K; Busaidy NL; Cabanillas ME; Wirth LJ; Stock S; Smith S; Lauriault V; Corsi-Travali S; Henry D; Burkard M; Hamor R; Bouhana K; Winski S; Wallace RD; Hartley D; Rhodes S; Reddy M; Brandhuber BJ; Andrews S; Rothenberg SM; Drilon A
Ann Oncol; 2018 Aug; 29(8):1869-1876. PubMed ID: 29912274
[TBL] [Abstract] [Full Text] [Related]
9. Characterization of Computed Tomography Imaging of Rearranged During Transfection-rearranged Lung cancer.
Saiki M; Kitazono S; Yoshizawa T; Dotsu Y; Ariyasu R; Koyama J; Sonoda T; Uchibori K; Nishikawa S; Yanagitani N; Horiike A; Ohyanagi F; Oikado K; Ninomiya H; Takeuchi K; Ishikawa Y; Nishio M
Clin Lung Cancer; 2018 Sep; 19(5):435-440.e1. PubMed ID: 29885946
[TBL] [Abstract] [Full Text] [Related]
10. DTCM-glutarimide Delays Growth and Radiosensitizes Glioblastoma.
Roberto GM; Paiva HH; Botelho de Souza LE; Pezuk JA; Vieira GM; de Oliveira HF; Umezawa K; Tone LG; Brassesco MS
Anticancer Agents Med Chem; 2018; 18(9):1323-1329. PubMed ID: 29683097
[TBL] [Abstract] [Full Text] [Related]
11. Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients.
Plenker D; Bertrand M; de Langen AJ; Riedel R; Lorenz C; Scheel AH; Müller J; Brägelmann J; Daßler-Plenker J; Kobe C; Persigehl T; Kluge A; Wurdinger T; Schellen P; Hartmann G; Zacherle T; Menon R; Thunnissen E; Büttner R; Griesinger F; Wolf J; Heukamp L; Sos ML; Heuckmann JM
Clin Cancer Res; 2018 Mar; 24(6):1337-1343. PubMed ID: 29284707
[No Abstract] [Full Text] [Related]
12. Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in kif5b-RET re-arranged non-small cell lung cancer with brain metastases.
Subbiah V; Berry J; Roxas M; Guha-Thakurta N; Subbiah IM; Ali SM; McMahon C; Miller V; Cascone T; Pai S; Tang Z; Heymach JV
Lung Cancer; 2015 Jul; 89(1):76-9. PubMed ID: 25982012
[TBL] [Abstract] [Full Text] [Related]
13. Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors.
Lovly CM; Heuckmann JM; de Stanchina E; Chen H; Thomas RK; Liang C; Pao W
Cancer Res; 2011 Jul; 71(14):4920-31. PubMed ID: 21613408
[TBL] [Abstract] [Full Text] [Related]
14. Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205-502.
Glaser B; Nesher Y; Barziliai S
J Reprod Med; 1994 Jun; 39(6):449-54. PubMed ID: 7932398
[TBL] [Abstract] [Full Text] [Related]
15. [Effect of MX-2, a morpholino anthracycline derivative, against human and rat glioma cells and experimental leptomeningeal tumors in rats].
Izumoto S; Arita N; Ushio Y; Hayakawa T; Ohnishi T; Taki T; Yamamoto H; Oku Y; Mogami H; Komeshima N
Gan To Kagaku Ryoho; 1988 May; 15(5):1765-9. PubMed ID: 3369870
[TBL] [Abstract] [Full Text] [Related]
16. An epithelial cell line (kns-62) derived from a brain metastasis of bronchial squamous cell carcinoma.
Takaki T
J Cancer Res Clin Oncol; 1980 Jan; 96(1):27-33. PubMed ID: 7358770
[TBL] [Abstract] [Full Text] [Related]